HCPCS Level II J0177: Injection, aflibercept hd, 1 mg
Commercial payers pay $343 on average nationally for this procedure.
HCPCS Level II code J0177 represents an injection of aflibercept hd, 1 mg, used as an intravitreal pharmacologic therapy for retinal vascular conditions; the service is an intravitreal injection typically performed in an ophthalmology clinic or ambulatory surgical center and billed as the drug administration for a 1 mg dose of aflibercept.
For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Chimeric Antigen Receptor (CAR) T-Cell Therapy, Antibody-Drug Conjugates.
Customize your policy alerts
Sign up for hcpcs J0177 policy alerts
Get alerted when payer policies referencing J0177 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial rates for J0177 cluster around the BUCA average of $343.10, with most large payers showing medians near $311–$324. Blue Cross Blue Shield and Cigna exhibit relatively tight interquartile spreads: BCBS P75–P25 = $362.30 - $312.00 = $50.30 and Cigna P75–P25 = $318.00 - $311.40 = $6.60, indicating consistent middle-range reimbursement. UnitedHealth Group and Aetna display wider dispersion: UnitedHealth Group P75–P25 = $333.10 - $311.40 = $21.70 and Aetna P75–P25 = $323.00 - $82.90 = $240.10, with Aetna showing the largest spread by far.
Payer-specific maxima and minima also vary: Aetna reaches a high of $3,424.00 and a low of $31.50, while UnitedHealth Group and Cigna have maximums of $650.50 and $415.60 respectively. Blue Cross Blue Shield’s rates are concentrated near its median of $335.60, reinforcing its narrow IQR. Overall, BUCA’s mean sits centrally among payer means, reflecting an average commercial position for this code.